BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, Zhang BH, Wu WZ, Shi YH, Wu B. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut. 2010;59:953-962. [PMID: 20442200 DOI: 10.1136/gut.2008.176271] [Cited by in Crossref: 183] [Cited by in F6Publishing: 180] [Article Influence: 16.6] [Reference Citation Analysis]
Number Citing Articles
1 Doratiotto S, Krause P, Serra MP, Marongiu F, Sini M, Koenig S, Laconi E. The growth pattern of transplanted normal and nodular hepatocytes. Histochem Cell Biol 2011;135:581-91. [PMID: 21528371 DOI: 10.1007/s00418-011-0813-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Wang WM, Xu Y, Wang YH, Sun HX, Sun YF, He YF, Zhu QF, Hu B, Zhang X, Xia JL, Qiu SJ, Zhou J, Yang XR, Fan J. HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma. Oncotarget 2017;8:47121-35. [PMID: 28454092 DOI: 10.18632/oncotarget.17004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
3 Xu M, Xie F, Qian G, Jing Y, Zhang S, Gao L, Zheng T, Wu M, Yang J, Wei L. Peritumoral ductular reaction: a poor postoperative prognostic factor for hepatocellular carcinoma. BMC Cancer. 2014;14:65. [PMID: 24495509 DOI: 10.1186/1471-2407-14-65] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
4 Lee S, Zhou P, Gupta A, Shin S. Reactive Ductules Are Associated With Angiogenesis and Tumor Cell Proliferation in Pediatric Liver Cancer. Hepatol Commun 2018;2:1199-212. [PMID: 30288475 DOI: 10.1002/hep4.1204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
5 Sonbol MB, Ahn DH, Bekaii-Saab T. Therapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies. Biomedicines 2019;7:E17. [PMID: 30857342 DOI: 10.3390/biomedicines7010017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
6 DePeralta DK, Wei L, Ghoshal S, Schmidt B, Lauwers GY, Lanuti M, Chung RT, Tanabe KK, Fuchs BC. Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. Cancer 2016;122:1216-27. [PMID: 26914713 DOI: 10.1002/cncr.29912] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 8.2] [Reference Citation Analysis]
7 Oikawa T, Kamiya A, Zeniya M, Chikada H, Hyuck AD, Yamazaki Y, Wauthier E, Tajiri H, Miller LD, Wang XW. Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology. 2013;57:1469-1483. [PMID: 23175232 DOI: 10.1002/hep.26159] [Cited by in Crossref: 137] [Cited by in F6Publishing: 123] [Article Influence: 17.1] [Reference Citation Analysis]
8 Ng L, Poon RTP, Pang R. Biomarkers for predicting future metastasis of human gastrointestinal tumors. Cell Mol Life Sci 2013;70:3631-56. [DOI: 10.1007/s00018-013-1266-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
9 Dou J, Gu N. Biomarkers of Cancer Stem Cells. In: Scatena R, Mordente A, Giardina B, editors. Advances in Cancer Stem Cell Biology. New York: Springer; 2012. pp. 45-67. [DOI: 10.1007/978-1-4614-0809-3_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Chan AW, Tong JH, Chan SL, Lai PB, To KF. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. Histopathology. 2014;64:935-950. [PMID: 24506513 DOI: 10.1111/his.12342] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 7.7] [Reference Citation Analysis]
11 Lima LDP, Machado CJ, Rodrigues JBSR, Vasconcellos LS, Junior EP, Vidigal PVT, Resende V. Immunohistochemical Coexpression of Epithelial Cell Adhesion Molecule and Alpha-Fetoprotein in Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:5970852. [PMID: 30112355 DOI: 10.1155/2018/5970852] [Reference Citation Analysis]
12 Li S, Li Q. Cancer stem cells and tumor metastasis (Review). Int J Oncol 2014;44:1806-12. [PMID: 24691919 DOI: 10.3892/ijo.2014.2362] [Cited by in Crossref: 83] [Cited by in F6Publishing: 74] [Article Influence: 11.9] [Reference Citation Analysis]
13 Lee TK, Guan XY, Ma S. Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34504325 DOI: 10.1038/s41575-021-00508-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Iliaz R, Akyuz U, Tekin D, Serilmez M, Evirgen S, Cavus B, Soydinc H, Duranyildiz D, Karaca C, Demir K, Besisik F, Kaymakoglu S, Akyuz F. Role of several cytokines and adhesion molecules in the diagnosis and prediction of survival of hepatocellular carcinoma. Arab J Gastroenterol 2016;17:164-7. [PMID: 27916547 DOI: 10.1016/j.ajg.2016.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
15 Zhan P, Ji YN, Yu LK. TP53 mutation is associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a meta-analysis. Hepatobiliary Surg Nutr. 2013;2:260-265. [PMID: 24570956 DOI: 10.3978/j.issn.2304-3881.2013.07.06] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
16 Iwahashi S, Utsunomiya T, Shimada M, Saito Y, Morine Y, Imura S, Ikemoto T, Mori H, Hanaoka J, Bando Y. High expression of cancer stem cell markers in cholangiolocellular carcinoma. Surg Today. 2013;43:654-660. [PMID: 23192764 DOI: 10.1007/s00595-012-0437-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
17 Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM, Ng IO, Man K, To KF, Lai PB, Lo CM, Guan XY, Chan KW. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology. 2012;55:807-820. [PMID: 21994122 DOI: 10.1002/hep.24739] [Cited by in Crossref: 157] [Cited by in F6Publishing: 145] [Article Influence: 17.4] [Reference Citation Analysis]
18 Dallas MR, Liu G, Chen WC, Thomas SN, Wirtz D, Huso DL, Konstantopoulos K. Divergent roles of CD44 and carcinoembryonic antigen in colon cancer metastasis. FASEB J. 2012;26:2648-2656. [PMID: 22415308 DOI: 10.1096/fj.12-203786] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
19 Yao H, Liu N, Lin MC, Zheng J. Positive feedback loop between cancer stem cells and angiogenesis in hepatocellular carcinoma. Cancer Lett 2016;379:213-9. [PMID: 27108065 DOI: 10.1016/j.canlet.2016.03.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
20 Wei J, Guo Y, Wang Y, Wu Z, Bo J, Zhang B, Zhu J, Han W. Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol 2021;18:792-804. [PMID: 32999455 DOI: 10.1038/s41423-020-00555-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
21 Jaferian S, Soleymaninejad M, Negahdari B, Eatemadi A. Stem cell, biomaterials and growth factors therapy for hepatocellular carcinoma. Biomed Pharmacother 2017;88:1046-53. [PMID: 28192881 DOI: 10.1016/j.biopha.2017.01.154] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
22 Jiao F, Hu H, Han T, Yuan C, Wang L, Jin Z, Guo Z, Wang L. Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells. Int J Mol Sci 2015;16:6677-93. [PMID: 25811929 DOI: 10.3390/ijms16046677] [Cited by in Crossref: 105] [Cited by in F6Publishing: 107] [Article Influence: 17.5] [Reference Citation Analysis]
23 Ye J, Wu X, Wu D, Wu P, Ni C, Zhang Z, Chen Z, Qiu F, Xu J, Huang J. miRNA-27b targets vascular endothelial growth factor C to inhibit tumor progression and angiogenesis in colorectal cancer. PLoS One. 2013;8:e60687. [PMID: 23593282 DOI: 10.1371/journal.pone.0060687] [Cited by in Crossref: 107] [Cited by in F6Publishing: 107] [Article Influence: 13.4] [Reference Citation Analysis]
24 Gong ZJ, Guo W, Sun YF, Zhang X, Qiu SJ, Zhou J, Fan J, Yang XR. Prognostic value of fever grade combined with neutrophil percentage in hepatocellular carcinoma patients presenting fever as the initial manifestation. Onco Targets Ther 2016;9:6281-90. [PMID: 27789960 DOI: 10.2147/OTT.S109023] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
25 Grosse-gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D, Kunz-schughart LA. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges: CD133 in human cancers. J Pathol 2013;229:355-78. [DOI: 10.1002/path.4086] [Cited by in Crossref: 185] [Cited by in F6Publishing: 182] [Article Influence: 20.6] [Reference Citation Analysis]
26 Zhu X, Wang F, Lin MC, Tian L, Fan W, Ng SS, Liu M, Huang J, Xu Z, Li D, Kung H. The 3' UTR variants in the GRP78 are not associated with overall survival in resectable hepatocellular carcinoma. PLoS One 2011;6:e17783. [PMID: 21445355 DOI: 10.1371/journal.pone.0017783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
27 Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, Cho JY, Yoo JE, Choi JS, Park YN. Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis. Hepatology. 2011;54:1707-1717. [PMID: 22045674 DOI: 10.1002/hep.24559] [Cited by in Crossref: 212] [Cited by in F6Publishing: 204] [Article Influence: 23.6] [Reference Citation Analysis]
28 Yang WJ, Sun YF, Jin AL, Lv LH, Zhu J, Wang BL, Zhou Y, Zhang CY, Wang H, Hu B, Wang PX, Te L, Pan BS, Zhou J, Fan J, Yang XR, Guo W. BCL11B suppresses tumor progression and stem cell traits in hepatocellular carcinoma by restoring p53 signaling activity. Cell Death Dis 2020;11:895. [PMID: 33093445 DOI: 10.1038/s41419-020-03115-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Feng H, Lin B, Zheng Y, Xu J, Zhou Y, Liu K, Zhu M, Li M. Overexpression of GATA5 Stimulates Paclitaxel to Inhibit Malignant Behaviors of Hepatocellular Carcinoma Cells. Cell J 2020;22:89-100. [PMID: 32779438 DOI: 10.22074/cellj.2020.6894] [Reference Citation Analysis]
30 Zhu SL, Ke Y, Peng YC, Ma L, Li H, Li LQ, Zhong JH. Comparison of long-term survival of patients with solitary large hepatocellular carcinoma of BCLC stage A after liver resection or transarterial chemoembolization: a propensity score analysis. PLoS One. 2014;9:e115834. [PMID: 25541684 DOI: 10.1371/journal.pone.0115834.ecollection] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Wang Y, Chen M, Wu Z, Tong C, Dai H, Guo Y, Liu Y, Huang J, Lv H, Luo C, Feng KC, Yang QM, Li XL, Han W. CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. Oncoimmunology. 2018;7:e1440169. [PMID: 29900044 DOI: 10.1080/2162402x.2018.1440169] [Cited by in Crossref: 82] [Cited by in F6Publishing: 68] [Article Influence: 27.3] [Reference Citation Analysis]
32 Hou X, Ye F, Li X, Liu W, Jing Y, Han Z, Wei L. Immune response involved in liver damage and the activation of hepatic progenitor cells during liver tumorigenesis. Cellular Immunology 2018;326:52-9. [DOI: 10.1016/j.cellimm.2017.08.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
33 Rountree CB, Mishra L, Willenbring H. Stem cells in liver diseases and cancer: recent advances on the path to new therapies. Hepatology. 2012;55:298-306. [PMID: 22030746 DOI: 10.1002/hep.24762] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 8.0] [Reference Citation Analysis]
34 Harding JJ, Khalil DN, Abou-Alfa GK. Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma? Dig Dis Sci 2019;64:918-27. [PMID: 30838478 DOI: 10.1007/s10620-019-05517-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
35 Maeda S, Nakagawa H. Roles of E-cadherin in Hepatocarcinogenesis. In: Nakao K, Minato N, Uemoto S, editors. Innovative Medicine. Tokyo: Springer Japan; 2015. pp. 71-7. [DOI: 10.1007/978-4-431-55651-0_6] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
36 Wakizaka K, Yokoo H, Kamiyama T, Kakisaka T, Ohira M, Tani M, Kato K, Fujii Y, Sugiyama K, Nagatsu A, Shimada S, Orimo T, Kamachi H, Matsuoka R, Taketomi A. CD133 and epithelial cell adhesion molecule expressions in the cholangiocarcinoma component are prognostic factors for combined hepatocellular cholangiocarcinoma. Hepatol Res 2020;50:258-67. [PMID: 31661725 DOI: 10.1111/hepr.13443] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
37 Wang X, Ren H, Zhao T, Chen J, Sun W, Sun Y, Ma W, Wang J, Gao C, Gao S. Stem cell factor is a novel independent prognostic biomarker for hepatocellular carcinoma after curative resection. Carcinogenesis. 2014;35:2283-2290. [PMID: 25086759 DOI: 10.1093/carcin/bgu162] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
38 Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu SJ, Shi RY, Hu B, Zhou J, Fan J. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology. 2013;57:1458-1468. [PMID: 23175471 DOI: 10.1002/hep.26151] [Cited by in Crossref: 224] [Cited by in F6Publishing: 227] [Article Influence: 28.0] [Reference Citation Analysis]
39 Abudoureyimu M, Zhou H, Zhi Y, Wang T, Feng B, Wang R, Chu X. Recent progress in the emerging role of exosome in hepatocellular carcinoma. Cell Prolif 2019;52:e12541. [PMID: 30397975 DOI: 10.1111/cpr.12541] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
40 You H, Ding W, Dang H, Jiang Y, Rountree CB. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology. 2011;54:879-889. [PMID: 21618573 DOI: 10.1002/hep.24450] [Cited by in Crossref: 123] [Cited by in F6Publishing: 137] [Article Influence: 12.3] [Reference Citation Analysis]
41 Sciarra A, Ronot M, Di Tommaso L, Raschioni C, Castera L, Belghiti J, Bedossa P, Vilgrain V, Roncalli M, Paradis V. TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma. Liver Int. 2015;Epub ahead of print. [PMID: 25865109 DOI: 10.1111/liv.12844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
42 Serra M, Columbano A, Perra A, Kowalik MA. Animal Models: A Useful Tool to Unveil Metabolic Changes in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E3318. [PMID: 33182674 DOI: 10.3390/cancers12113318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Hu YY, Du XY, Zhan AL, Zhou L, Jiang Q, Niu YM, Shen M. Vascular endothelial growth factor polymorphisms are associated with osteosarcoma susceptibility. Oncotarget 2016;7:47711-9. [PMID: 27351225 DOI: 10.18632/oncotarget.10278] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
44 Majumdar A, Curley SA, Wu X, Brown P, Hwang JP, Shetty K, Yao ZX, He AR, Li S, Katz L. Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2012;9:530-538. [PMID: 22710573 DOI: 10.1038/nrgastro.2012.114] [Cited by in Crossref: 90] [Cited by in F6Publishing: 92] [Article Influence: 10.0] [Reference Citation Analysis]
45 Liao W, Liu W, Yuan Q, Liu X, Ou Y, He S, Yuan S, Qin L, Chen Q, Nong K, Mei M, Huang J. Silencing of DLGAP5 by siRNA significantly inhibits the proliferation and invasion of hepatocellular carcinoma cells. PLoS One 2013;8:e80789. [PMID: 24324629 DOI: 10.1371/journal.pone.0080789] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
46 Hernandez C, Huebener P, Pradere JP, Antoine DJ, Friedman RA, Schwabe RF. HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis. J Clin Invest 2018;128:2436-51. [PMID: 29558367 DOI: 10.1172/JCI91786] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
47 Zhang Y, Zeng S, Ma J, Deng G, Qu Y, Guo C, Shen H. Nestin overexpression in hepatocellular carcinoma associates with epithelial-mesenchymal transition and chemoresistance. J Exp Clin Cancer Res 2016;35:111. [PMID: 27412382 DOI: 10.1186/s13046-016-0387-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
48 Kong W, Gao M, Jin Y, Huang W, Huang Z, Xie Z. Prognostic model of patients with liver cancer based on tumor stem cell content and immune process. Aging (Albany NY) 2020;12:16555-78. [PMID: 32852285 DOI: 10.18632/aging.103832] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
49 Ji YN, Wang Q, Xue J. TP53 immunohistochemical expression is associated with the poor outcome for hepatocellular carcinoma: evidence from a meta-analysis. Tumour Biol 2014;35:1653-9. [PMID: 24078450 DOI: 10.1007/s13277-013-1228-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
50 Bouattour M, Payancé A, Wassermann J. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol 2015; 7(20): 2245-2263 [PMID: 26380650 DOI: 10.4254/wjh.v7.i20.2245] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
51 Ding J, Wang H. Multiple interactive factors in hepatocarcinogenesis. Cancer Lett. 2014;346:17-23. [PMID: 24374016 DOI: 10.1016/j.canlet.2013.12.024] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 7.9] [Reference Citation Analysis]
52 Xu J, Ding T, He Q, Yu X, Wu W, Jia W, Yun J, Zhang Y, Shi M, Shao C, Pan W, Yin X, Min J, Zhuang S, Zheng L. An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma. Journal of Hepatology 2012;57:313-21. [DOI: 10.1016/j.jhep.2012.03.027] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
53 Zahran AM, Abdel-Rahim MH, Refaat A, Sayed M, Othman MM, Khalak LMR, Hetta HF. Circulating hematopoietic stem cells, endothelial progenitor cells and cancer stem cells in hepatocellular carcinoma patients: contribution to diagnosis and prognosis. Acta Oncol 2020;59:33-9. [PMID: 31478425 DOI: 10.1080/0284186X.2019.1657940] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
54 Yu DD, Jing YY, Guo SW, Ye F, Lu W, Li Q, Dong YL, Gao L, Yang YT, Yang Y, Wu MC, Wei LX. Overexpression Of Hepatocyte Nuclear Factor-1beta Predicting Poor Prognosis Is Associated With Biliary Phenotype In Patients With Hepatocellular Carcinoma. Sci Rep 2015;5:13319. [PMID: 26311117 DOI: 10.1038/srep13319] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
55 Song L, Chen X, Wang P, Gao S, Qu C, Liu L. Effects of baicalein on pancreatic cancer stem cells via modulation of sonic Hedgehog pathway. Acta Biochim Biophys Sin (Shanghai) 2018;50:586-96. [PMID: 29697746 DOI: 10.1093/abbs/gmy045] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
56 Kowalik MA, Sulas P, Ledda-Columbano GM, Giordano S, Columbano A, Perra A. Cytokeratin-19 positivity is acquired along cancer progression and does not predict cell origin in rat hepatocarcinogenesis. Oncotarget 2015;6:38749-63. [PMID: 26452031 DOI: 10.18632/oncotarget.5501] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
57 Chai S, Tong M, Ng KY, Kwan PS, Chan YP, Fung TM, Lee TK, Wong N, Xie D, Yuan YF, Guan XY, Ma S. Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133. Oncotarget 2014;5:5725-35. [PMID: 25015418 DOI: 10.18632/oncotarget.2167] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 8.5] [Reference Citation Analysis]
58 You ML, Chen YJ, Chong QY, Wu MM, Pandey V, Chen RM, Liu L, Ma L, Wu ZS, Zhu T, Lobie PE. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent. Oncotarget 2017;8:39323-44. [PMID: 28445151 DOI: 10.18632/oncotarget.16950] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
59 Niu ZS, Niu XJ, Wang M. Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival. World J Hepatol 2015; 7(1): 7-27 [PMID: 25624992 DOI: 10.4254/wjh.v7.i1.7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
60 Gao Q, Shi Y, Wang X, Zhou J, Qiu S, Fan J. Translational medicine in hepatocellular carcinoma. Front Med. 2012;6:122-133. [PMID: 22573220 DOI: 10.1007/s11684-012-0193-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
61 Ko CJ, Li CJ, Wu MY, Chu PY. Overexpression of epithelial cell adhesion molecule as a predictor of poor outcome in patients with hepatocellular carcinoma. Exp Ther Med 2018;16:4810-6. [PMID: 30542436 DOI: 10.3892/etm.2018.6794] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
62 Lee TK, Cheung VC, Ng IO. Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma. Cancer Lett. 2013;338:101-109. [PMID: 22579789 DOI: 10.1016/j.canlet.2012.05.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
63 Yang B, Liu H, Yang H, Chen W, Wu J, Feng X, Tong R, Yu H, Chen Y, Lv Z, Sun W, He B, Wu J, Yu G, Mao Z, Zheng S. Combinatorial photochemotherapy on liver cancer stem cells with organoplatinum(ii) metallacage-based nanoparticles. J Mater Chem B. 2019;7:6476-6487. [PMID: 31465082 DOI: 10.1039/c9tb01299k] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
64 Cathcart MC, Gately K, Cummins R, Drakeford C, W. Kay E, O'byrne KJ, Pidgeon GP. Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2014;1842:747-55. [DOI: 10.1016/j.bbadis.2014.01.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
65 Srivastava S, Wong KF, Ong CW, Huak CY, Yeoh KG, Teh M, Luk JM, Salto-Tellez M. A morpho-molecular prognostic model for hepatocellular carcinoma. Br J Cancer. 2012;107:334-339. [PMID: 22713659 DOI: 10.1038/bjc.2012.230] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
66 Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci. 2011;1:5. [PMID: 21711594 DOI: 10.1186/2045-3701-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Liu LL, Fu D, Ma Y, Shen XZ. The power and the promise of liver cancer stem cell markers. Stem Cells Dev. 2011;20:2023-2030. [PMID: 21651381 DOI: 10.1089/scd.2011.0012] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 6.7] [Reference Citation Analysis]
68 Lencioni R. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. Crit Rev Oncol Hematol. 2012;83:216-224. [PMID: 22142656 DOI: 10.1016/j.critrevonc.2011.10.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
69 Li M, Xin Y, Fu S, Liu Z, Li Y, Hu B, Chen S, Liang C, Lu L. Corona Enhancement and Mosaic Architecture for Prognosis and Selection Between of Liver Resection Versus Transcatheter Arterial Chemoembolization in Single Hepatocellular Carcinomas >5 cm Without Extrahepatic Metastases: An Imaging-Based Retrospective Study. Medicine (Baltimore) 2016;95:e2458. [PMID: 26765441 DOI: 10.1097/MD.0000000000002458] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
70 Liu HQ, An JZ, Liu J, Yang YF, Zhang HX, Zhao BY, Li JB, Yang HS, Chen ZN, Xing JL. Leukocyte telomere length predicts overall survival in hepatocellular carcinoma treated with transarterial chemoembolization. Carcinogenesis. 2012;33:1040-1045. [PMID: 22318909 DOI: 10.1093/carcin/bgs098] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
71 Wang Q, Tian X, Zhang C, Wang Q. Upregulation of vasohibin-1 expression with angiogenesis and poor prognosis of hepatocellular carcinoma after curative surgery. Med Oncol 2012;29:2727-36. [DOI: 10.1007/s12032-011-0106-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
72 Pusterla T, Nèmeth J, Stein I, Wiechert L, Knigin D, Marhenke S, Longerich T, Kumar V, Arnold B, Vogel A. Receptor for advanced glycation endproducts (RAGE) is a key regulator of oval cell activation and inflammation-associated liver carcinogenesis in mice. Hepatology. 2013;58:363-373. [PMID: 23504974 DOI: 10.1002/hep.26395] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 7.3] [Reference Citation Analysis]
73 Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. European Journal of Cancer 2012;48:1977-87. [DOI: 10.1016/j.ejca.2012.01.015] [Cited by in Crossref: 64] [Cited by in F6Publishing: 71] [Article Influence: 7.1] [Reference Citation Analysis]
74 Wang JH, Huang ST, Zhang L, Liu ZG, Liang RX, Jiang SW, Jiang YN, Yu XJ, Jiang YC, Li XZ, Zhang PF, Wen ZS, Zheng M. Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinoma. Cancer Med 2019;8:1315-25. [PMID: 30741466 DOI: 10.1002/cam4.1894] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
75 Zhu J, Yang Y, Ma C, Zhang G, Wang K, Hu S. CEACAM1 Cytoplastic Expression is Closely Related to Tumor Angiogenesis and Poorer Relapse-free Survival After Curative Resection of Hepatocellular Carcinoma. World J Surg 2011;35:2259-65. [DOI: 10.1007/s00268-011-1119-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
76 Liu Y, Liu DL, Dong LL, Wen D, Shi DM, Zhou J, Fan J, Wu WZ. miR-612 suppresses stem cell-like property of hepatocellular carcinoma cells by modulating Sp1/Nanog signaling. Cell Death Dis 2016;7:e2377. [PMID: 27685621 DOI: 10.1038/cddis.2016.282] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
77 Zeng Z, Cao Z, Zhang E, Huang H, Tang Y. Elevated CDK5R1 predicts worse prognosis in hepatocellular carcinoma based on TCGA data. Biosci Rep 2021;41:BSR20203594. [PMID: 33346796 DOI: 10.1042/BSR20203594] [Reference Citation Analysis]
78 Wang Q, Zhong YJ, Yuan JP, Shao LH, Zhang J, Tang L, Liu SP, Hong YP, Firestone RA, Li Y. Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study. J Transl Med 2013;11:192. [PMID: 23961994 DOI: 10.1186/1479-5876-11-192] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
79 Feng J, Zhu R, Chang C, Yu L, Cao F, Zhu G, Chen F, Xia H, Lv F, Zhang S, Sun L. CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection. PLoS One. 2016;11:e0151501. [PMID: 26977595 DOI: 10.1371/journal.pone.0151501] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
80 Zhang X, Jiang P, Shuai L, Chen K, Li Z, Zhang Y, Jiang Y, Li X. miR-589-5p inhibits MAP3K8 and suppresses CD90+ cancer stem cells in hepatocellular carcinoma. J Exp Clin Cancer Res 2016;35:176. [PMID: 27835990 DOI: 10.1186/s13046-016-0452-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
81 Chung GE, Lee JH, Yoon JH, Myung SJ, Lee K, Jang JJ, Lee JM, Kim SH, Suh KS, Kim YJ. Prognostic implications of tumor vascularity and its relationship to cytokeratin 19 expression in patients with hepatocellular carcinoma. Abdom Imaging. 2012;37:439-446. [PMID: 21584634 DOI: 10.1007/s00261-011-9756-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
82 Tong CM, Ma S, Guan XY. Biology of hepatic cancer stem cells. J Gastroenterol Hepatol. 2011;26:1229-1237. [PMID: 21557770 DOI: 10.1111/j.1440-1746.2011.06762.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
83 Francois-Vaughan H, Adebayo AO, Brilliant KE, Parry NMA, Gruppuso PA, Sanders JA. Persistent effect of mTOR inhibition on preneoplastic foci progression and gene expression in a rat model of hepatocellular carcinoma. Carcinogenesis 2016;37:408-19. [PMID: 26905589 DOI: 10.1093/carcin/bgw016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
84 Sakabe T, Azumi J, Umekita Y, Toriguchi K, Hatano E, Hirooka Y, Shiota G. Prognostic relevance of miR-137 in patients with hepatocellular carcinoma. Liver Int 2017;37:271-9. [PMID: 27473646 DOI: 10.1111/liv.13213] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
85 Li Y, Ma X, Zhang J, Liu X, Liu L. Prognostic value of microvessel density in hepatocellular carcinoma patients: a meta-analysis. Int J Biol Markers. 2014;29:e279-e287. [PMID: 24803279 DOI: 10.5301/jbm.5000087] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
86 Shi DM, Li LX, Bian XY, Shi XJ, Lu LL, Zhou HX, Pan TJ, Zhou J, Fan J, Wu WZ. miR-296-5p suppresses EMT of hepatocellular carcinoma via attenuating NRG1/ERBB2/ERBB3 signaling. J Exp Clin Cancer Res 2018;37:294. [PMID: 30486894 DOI: 10.1186/s13046-018-0957-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 11.0] [Reference Citation Analysis]
87 Lo RC, Ng IO. Hepatic progenitor cells: their role and functional significance in the new classification of primary liver cancers. Liver Cancer 2013;2:84-92. [PMID: 24159600 DOI: 10.1159/000343844] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
88 Hu B, Li H, Guo W, Sun Y, Zhang X, Tang W, Yang L, Xu Y, Tang X, Ding G, Qiu S, Zhou J, Li Y, Fan J, Yang X. Establishment of a hepatocellular carcinoma patient‐derived xenograft platform and its application in biomarker identification. Int J Cancer 2019;146:1606-17. [DOI: 10.1002/ijc.32564] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
89 Mao Y, Xu S, Hu W, Huang J, Wang J, Zhang R, Li S. Imaging features predict prognosis of patients with combined hepatocellular-cholangiocarcinoma. Clin Radiol 2017;72:129-35. [PMID: 27916195 DOI: 10.1016/j.crad.2016.11.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
90 Wang K, Guo W, Li N, Shi J, Zhang C, Lau WY, Wu M, Cheng S. Alpha-1-fucosidase as a prognostic indicator for hepatocellular carcinoma following hepatectomy: a large-scale, long-term study. Br J Cancer. 2014;110:1811-1819. [PMID: 24569461 DOI: 10.1038/bjc.2014.102] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
91 Dai H, Tong C, Shi D, Chen M, Guo Y, Chen D, Han X, Wang H, Wang Y, Shen P. Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. Oncoimmunology. 2020;9:1846926. [PMID: 33312759 DOI: 10.1080/2162402x.2020.1846926] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
92 Zhu SL, Ke Y, Peng YC, Ma L, Li H, Li LQ, Zhong JH. Comparison of long-term survival of patients with solitary large hepatocellular carcinoma of BCLC stage A after liver resection or transarterial chemoembolization: a propensity score analysis. PLoS One. 2014;9:e115834. [PMID: 25541684 DOI: 10.1371/journal.pone.0115834] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
93 Yim SY, Lee JS. An Overview of the Genomic Characterization of Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1077-88. [PMID: 34522690 DOI: 10.2147/JHC.S270533] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Fleming BD, Ho M. Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer. Toxins (Basel) 2016;8:E274. [PMID: 27669301 DOI: 10.3390/toxins8100274] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
95 Luk JM, Burchard J, Zhang C, Liu AM, Wong KF, Shek FH, Lee NP, Fan ST, Poon RT, Ivanovska I. DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival. J Biol Chem. 2011;286:30706-30713. [PMID: 21737452 DOI: 10.1074/jbc.m111.229831] [Cited by in Crossref: 110] [Cited by in F6Publishing: 69] [Article Influence: 11.0] [Reference Citation Analysis]
96 Zhao B, Lu J, Yin J, Liu H, Guo X, Yang Y, Ge N, Zhu Y, Zhang H, Xing J. A functional polymorphism in PER3 gene is associated with prognosis in hepatocellular carcinoma. Liver Int. 2012;32:1451-1459. [PMID: 22809120 DOI: 10.1111/j.1478-3231.2012.02849.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
97 Lai KP, Li JW, Cheung A, Li R, Billah MB, Chan TF, Wong CKC. Transcriptome sequencing reveals prenatal PFOS exposure on liver disorders. Environmental Pollution 2017;223:416-25. [DOI: 10.1016/j.envpol.2017.01.041] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
98 Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. J Clin Invest 2013;123:1911-8. [PMID: 23635789 DOI: 10.1172/JCI66024] [Cited by in Crossref: 310] [Cited by in F6Publishing: 223] [Article Influence: 38.8] [Reference Citation Analysis]
99 Fatourou E, Koskinas J, Karandrea D, Palaiologou M, Syminelaki T, Karanikolas M, Felekouras E, Antoniou E, Manesis EK, Delladetsima J. Keratin 19 protein expression is an independent predictor of survival in human hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2015;27:1094-1102. [PMID: 26011233 DOI: 10.1097/meg.0000000000000398] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
100 Seino S, Tsuchiya A, Watanabe Y, Kawata Y, Kojima Y, Ikarashi S, Yanai H, Nakamura K, Kumaki D, Hirano M, Funakoshi K, Aono T, Sakai T, Sakata J, Takamura M, Kawai H, Yamagiwa S, Wakai T, Terai S. Clinical outcome of hepatocellular carcinoma can be predicted by the expression of hepatic progenitor cell markers and serum tumour markers. Oncotarget 2018;9:21844-60. [PMID: 29774107 DOI: 10.18632/oncotarget.25074] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
101 Cao HH, Zheng CP, Wang SH, Wu JY, Shen JH, Xu XE, Fu JH, Wu ZY, Li EM, Xu LY. A molecular prognostic model predicts esophageal squamous cell carcinoma prognosis. PLoS One 2014;9:e106007. [PMID: 25153136 DOI: 10.1371/journal.pone.0106007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
102 Jiang J, Yang P, Guo Z, Yang R, Yang H, Yang F, Li L, Xiang B. Overexpression of microRNA-21 strengthens stem cell-like characteristics in a hepatocellular carcinoma cell line. World J Surg Oncol 2016;14:278. [PMID: 27793160 DOI: 10.1186/s12957-016-1028-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
103 Lau EY, Ho NP, Lee TK. Cancer Stem Cells and Their Microenvironment: Biology and Therapeutic Implications. Stem Cells Int 2017;2017:3714190. [PMID: 28337221 DOI: 10.1155/2017/3714190] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 17.5] [Reference Citation Analysis]
104 Wen T, Jin C, Facciorusso A, Donadon M, Han HS, Mao Y, Dai C, Cheng S, Zhang B, Peng B, Du S, Jia C, Xu F, Shi J, Sun J, Zhu P, Nara S, Millis JM; MDT of West China Hospital*. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg Nutr 2018;7:353-71. [PMID: 30498711 DOI: 10.21037/hbsn.2018.08.01] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
105 Zhong C, Wu JD, Fang MM, Pu LY. Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis. Tumour Biol 2015;36:7623-30. [PMID: 25921286 DOI: 10.1007/s13277-015-3487-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
106 Quagliata L, Schlageter M, Quintavalle C, Tornillo L, Terracciano LM. Identification of New Players in Hepatocarcinogenesis: Limits and Opportunities of Using Tissue Microarray (TMA). Microarrays (Basel) 2014;3:91-102. [PMID: 27600338 DOI: 10.3390/microarrays3020091] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
107 Wang N, Wang S, Li MY, Hu BG, Liu LP, Yang SL, Yang S, Gong Z, Lai PBS, Chen GG. Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies. Ther Adv Med Oncol. 2018;10:1758835918816287. [PMID: 30622654 DOI: 10.1177/1758835918816287] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 14.0] [Reference Citation Analysis]
108 Petrizzo A, Mauriello A, Tornesello ML, Buonaguro FM, Tagliamonte M, Buonaguro L. Cellular prognostic markers in hepatitis-related hepatocellular carcinoma. Infect Agent Cancer 2018;13:10. [PMID: 29599818 DOI: 10.1186/s13027-018-0183-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
109 Wu H, Chen P, Liao R, Li YW, Yi Y, Wang JX, Sun TW, Zhou J, Shi YH, Yang XR. Overexpression of galectin-1 is associated with poor prognosis in human hepatocellular carcinoma following resection. J Gastroenterol Hepatol. 2012;27:1312-1319. [PMID: 22432916 DOI: 10.1111/j.1440-1746.2012.07130.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
110 Huang M, Chen C, Geng J, Han D, Wang T, Xie T, Wang L, Wang Y, Wang C, Lei Z, Chu X. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. Cancer Lett 2017;398:12-21. [PMID: 28377178 DOI: 10.1016/j.canlet.2017.03.038] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 11.8] [Reference Citation Analysis]
111 Zhang C, Xu Y, Zhao J, Fan L, Jiang G, Li R, Ling Y, Wu M, Wei L. Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma. Ann Surg Oncol. 2011;18:2373-2380. [PMID: 21331808 DOI: 10.1245/s10434-011-1599-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
112 Zhou Y, Wang B, Wu J, Zhang C, Zhou Y, Yang X, Zhou J, Guo W, Fan J. Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection. BMC Cancer 2016;16:506. [PMID: 27439521 DOI: 10.1186/s12885-016-2526-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 6.6] [Reference Citation Analysis]
113 Nogueira AB, Nogueira AB, Costa AL, Lima FR, Siqueira SA, Teixeira MJ. Hepatocellular carcinoma may display elevated nestin expression in endothelial cells: experimental study. Sao Paulo Med J 2015;133:135-40. [PMID: 26018884 DOI: 10.1590/1516-3180.2014.8670910] [Reference Citation Analysis]
114 Ji J, Wang XW. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol. 2012;39:461-472. [PMID: 22846863 DOI: 10.1053/j.seminoncol.2012.05.011] [Cited by in Crossref: 135] [Cited by in F6Publishing: 131] [Article Influence: 15.0] [Reference Citation Analysis]
115 Khare T, Khare S, Ibdah JA. Proteomics approaches for early detection and targeted therapy of hepatocellular carcinoma. World J Gastrointest Oncol 2017; 9(1): 1-3 [PMID: 28144394 DOI: 10.4251/wjgo.v9.i1.1] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
116 Chen L, Fan J, Chen H, Meng Z, Chen Z, Wang P, Liu L. The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases. Sci Rep. 2014;4:5911. [PMID: 25081383 DOI: 10.1038/srep05911] [Cited by in Crossref: 81] [Cited by in F6Publishing: 91] [Article Influence: 11.6] [Reference Citation Analysis]
117 Zhang X, Liu S, Shen C, Wu Y, Zhang L, Chen X, Lu F. DNA methylation consistency implicates the primary tumor cell origin of recurrent hepatocellular carcinoma. Epigenomics 2015;7:581-92. [PMID: 25815780 DOI: 10.2217/epi.15.23] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
118 Li J, Liu Y, Yan Z, Wan X, Xia Y, Wang K, Liu J, Lau WY, Wu M, Shen F. A nomogram predicting pulmonary metastasis of hepatocellular carcinoma following partial hepatectomy. Br J Cancer 2014;110:1110-7. [PMID: 24481404 DOI: 10.1038/bjc.2014.19] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
119 Khare T, Khare S, Angdisen JJ, Zhang Q, Stuckel A, Mooney BP, Ridenhour SE, Gitan RS, Hammoud GM, Ibdah JA. Defects in long-chain 3-hydroxy acyl-CoA dehydrogenase lead to hepatocellular carcinoma: A novel etiology of hepatocellular carcinoma. Int J Cancer 2020;147:1461-73. [PMID: 32115688 DOI: 10.1002/ijc.32943] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
120 Rong W, Yang L, Yin L, Gao Y, Xiao T, Cheng S. PSG9 promotes angiogenesis by stimulating VEGFA production and is associated with poor prognosis in hepatocellular carcinoma. Sci China Life Sci 2017;60:528-35. [PMID: 28078509 DOI: 10.1007/s11427-016-0226-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
121 Zhong WQ, Chen G, Zhang W, Xiong XP, Zhao Y, Liu B, Zhao YF. M2-polarized macrophages in keratocystic odontogenic tumor: relation to tumor angiogenesis. Sci Rep 2015;5:15586. [PMID: 26508096 DOI: 10.1038/srep15586] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
122 Sun YF, Wu L, Liu SP, Jiang MM, Hu B, Zhou KQ, Guo W, Xu Y, Zhong Y, Zhou XR, Zhang ZF, Liu G, Liu S, Shi YH, Ji Y, Du M, Li NN, Li GB, Zhao ZK, Huang XY, Xu LQ, Yu QC, Peng DH, Qiu SJ, Sun HC, Dean M, Wang XD, Chung WY, Dennison AR, Zhou J, Hou Y, Fan J, Yang XR. Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. Nat Commun 2021;12:4091. [PMID: 34215748 DOI: 10.1038/s41467-021-24386-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
123 Yang B, Li M, Tang W, Liu W, Zhang S, Chen L, Xia J. Dynamic network biomarker indicates pulmonary metastasis at the tipping point of hepatocellular carcinoma. Nat Commun 2018;9:678. [PMID: 29445139 DOI: 10.1038/s41467-018-03024-2] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 21.3] [Reference Citation Analysis]
124 Shigesawa T, Maehara O, Suda G, Natsuizaka M, Kimura M, Shimazaki T, Yamamoto K, Yamada R, Kitagataya T, Nakamura A, Suzuki K, Ohara M, Kawagishi N, Umemura M, Nakai M, Sho T, Morikawa K, Ogawa K, Ohnishi S, Sugiyama M, Mizokami M, Takeda H, Sakamoto N. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling. Carcinogenesis 2021;42:58-69. [PMID: 32449510 DOI: 10.1093/carcin/bgaa049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
125 Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci. 2011;1:5. [PMID: 21711594 DOI: 10.1186/2045-3701-1-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 5.8] [Reference Citation Analysis]
126 Wang X, Deng Q, Feng K, Chen S, Jiang J, Xia F, Ma K, Bie P. Insufficient radiofrequency ablation promotes hepatocellular carcinoma cell progression via autophagy and the CD133 feedback loop. Oncol Rep. 2018;40:241-251. [PMID: 29749472 DOI: 10.3892/or.2018.6403] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
127 Yoshida S, Kornek M, Ikenaga N, Schmelzle M, Masuzaki R, Csizmadia E, Wu Y, Robson SC, Schuppan D. Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma: Hepatology. Hepatology 2013;58:1667-80. [DOI: 10.1002/hep.26526] [Cited by in Crossref: 66] [Cited by in F6Publishing: 71] [Article Influence: 8.3] [Reference Citation Analysis]
128 Sung JJ, Noh SJ, Bae JS, Park HS, Jang KY, Chung MJ, Moon WS. Immunohistochemical Expression and Clinical Significance of Suggested Stem Cell Markers in Hepatocellular Carcinoma. J Pathol Transl Med 2016;50:52-7. [PMID: 26581206 DOI: 10.4132/jptm.2015.10.09] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
129 Hoseini SS, Cheung NV. Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies. Cancer Lett. 2017;399:44-52. [PMID: 28428075 DOI: 10.1016/j.canlet.2017.04.013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
130 Miao S, Qiu T, Zhao Y, Wang H, Sun X, Wang Y, Xuan Y, Qin Y, Jiao W. Overexpression of S100A13 protein is associated with tumor angiogenesis and poor survival in patients with early-stage non-small cell lung cancer. Thorac Cancer 2018;9:1136-44. [PMID: 30047626 DOI: 10.1111/1759-7714.12797] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
131 Berretta M, Cavaliere C, Alessandrini L, Stanzione B, Facchini G, Balestreri L, Perin T, Canzonieri V. Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget. 2017;8:14192-14220. [PMID: 28077782 DOI: 10.18632/oncotarget.13929] [Cited by in Crossref: 33] [Cited by in F6Publishing: 41] [Article Influence: 8.3] [Reference Citation Analysis]
132 Zhang Q, Lu C, Fang T, Wang Y, Hu W, Qiao J, Liu B, Liu J, Chen N, Li M, Zhu R. Notch3 functions as a regulator of cell self-renewal by interacting with the β-catenin pathway in hepatocellular carcinoma. Oncotarget 2015;6:3669-79. [PMID: 25668819 DOI: 10.18632/oncotarget.2898] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
133 Wu Y, Zhang J, Zhang X, Zhou H, Liu G, Li Q. Cancer Stem Cells: A Potential Breakthrough in HCC-Targeted Therapy. Front Pharmacol 2020;11:198. [PMID: 32210805 DOI: 10.3389/fphar.2020.00198] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
134 Lee SH, Yim SY, Shim J, Lee J. Molecular Subtypes and Genomic Signatures of Hepatocellular Carcinoma for Prognostication and Therapeutic Decision-Making. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 109-23. [DOI: 10.1007/978-3-030-21540-8_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
135 Yun WJ, Shin E, Lee K, Jung HY, Kim SH, Park YN, Yu E, Jang JJ. Clinicopathologic implication of hepatic progenitor cell marker expression in hepatoblastoma. Pathol Res Pract. 2013;209:568-573. [PMID: 23920322 DOI: 10.1016/j.prp.2013.06.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
136 Fakiruddin KS, Ghazalli N, Lim MN, Zakaria Z, Abdullah S. Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised Tumour. Int J Mol Sci 2018;19:E2188. [PMID: 30060445 DOI: 10.3390/ijms19082188] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
137 Lanza E, Donadon M, Poretti D, Pedicini V, Tramarin M, Roncalli M, Rhee H, Park YN, Torzilli G. Transarterial Therapies for Hepatocellular Carcinoma. Liver Cancer 2016;6:27-33. [PMID: 27995085 DOI: 10.1159/000449347] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
138 Bae JS, Choi HN, Noh SJ, Park BH, Jang KY, Park CK, Moon WS. Expression of K19 and K7 in dysplastic nodules and hepatocellular carcinoma. Oncol Lett 2012;4:213-20. [PMID: 22844356 DOI: 10.3892/ol.2012.731] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
139 Zhao Q, Zhou H, Liu Q, Cao Y, Wang G, Hu A, Ruan L, Wang S, Bo Q, Chen W, Hu C, Xu D, Tao F, Cao J, Ge Y, Yu Z, Li L, Wang H. Prognostic value of the expression of cancer stem cell-related markers CD133 and CD44 in hepatocellular carcinoma: From patients to patient-derived tumor xenograft models. Oncotarget. 2016;7:47431-47443. [PMID: 27329727 DOI: 10.18632/oncotarget.10164] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
140 Alhabbab RY. Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells. Front Genet 2020;11:312. [PMID: 32391048 DOI: 10.3389/fgene.2020.00312] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
141 Zhan P, Qian Q, Yu LK. Prognostic significance of vascular endothelial growth factor expression in hepatocellular carcinoma tissue: a meta-analysis. Hepatobiliary Surg Nutr. 2013;2:148-155. [PMID: 24570933 DOI: 10.3978/j.issn.2304-3881.2013.06.06] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
142 Wang WQ, Liu L, Xu HX, Wu CT, Xiang JF, Xu J, Liu C, Long J, Ni QX, Yu XJ. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma. Br J Surg. 2016;103:1189-1199. [PMID: 27256393 DOI: 10.1002/bjs.10187] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 11.4] [Reference Citation Analysis]
143 Su R, Nan H, Guo H, Ruan Z, Jiang L, Song Y, Nan K. Associations of components of PTEN/AKT/mTOR pathway with cancer stem cell markers and prognostic value of these biomarkers in hepatocellular carcinoma. Hepatol Res. 2016; Epub ahead of print. [PMID: 26932478 DOI: 10.1111/hepr.12687] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
144 Buonaguro L, Tagliamonte M, Petrizzo A, Damiano E, Tornesello ML, Buonaguro FM. Cellular prognostic markers in hepatocellular carcinoma. Future Oncol 2015;11:1591-8. [PMID: 26043213 DOI: 10.2217/fon.15.39] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
145 Shim JH, Jun MJ, Han S, Lee YJ, Lee SG, Kim KM, Lim YS, Lee HC. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Ann Surg. 2015;261:939-946. [PMID: 24950276 DOI: 10.1097/sla.0000000000000747] [Cited by in Crossref: 128] [Cited by in F6Publishing: 67] [Article Influence: 21.3] [Reference Citation Analysis]
146 Zhan P, Ji YN. Prognostic significance of TP53 expression for patients with hepatocellular carcinoma: a meta-analysis. Hepatobiliary Surg Nutr. 2014;3:11-17. [PMID: 24696834 DOI: 10.3978/j.issn.2304-3881.2014.01.03] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
147 Liu WH, You N, Zhang N, Yan HT, Wang T, Huang Z, Liu HB, Tang LJ. Interpretation of interlocking key issues of cancer stem cells in malignant solid tumors. Cell Oncol (Dordr) 2012;35:397-409. [PMID: 23179790 DOI: 10.1007/s13402-012-0110-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
148 Wang F, Jing X, Wang T, Li G, Li T, Zhang Q, Huang Y, Li J, Wang Y, Gao Y. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm. Am J Clin Pathol. 2012;137:937-945. [PMID: 22586053 DOI: 10.1309/ajcp0kzz5dsigmny] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
149 Ye F, Jing YY, Guo SW, Yu GF, Fan QM, Qu FF, Gao L, Yang Y, Wu D, Meng Y, Yu FH, Wei LX. Proliferative ductular reactions correlate with hepatic progenitor cell and predict recurrence in HCC patients after curative resection. Cell Biosci 2014;4:50. [PMID: 25197550 DOI: 10.1186/2045-3701-4-50] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
150 Ogawa K, Tanaka S, Matsumura S, Murakata A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Tanabe M, Arii S. EpCAM-Targeted Therapy for Human Hepatocellular Carcinoma. Ann Surg Oncol 2014;21:1314-22. [DOI: 10.1245/s10434-013-3430-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
151 Cao HH, Zhang SY, Shen JH, Wu ZY, Wu JY, Wang SH, Li EM, Xu LY. A three-protein signature and clinical outcome in esophageal squamous cell carcinoma. Oncotarget. 2015;6:5435-5448. [PMID: 25605255 DOI: 10.18632/oncotarget.3102] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
152 Sanders JA, Brilliant KE, Clift D, Patel A, Cerretti B, Claro P, Mills DR, Hixson DC, Gruppuso PA. The inhibitory effect of rapamycin on the oval cell response and development of preneoplastic foci in the rat. Exp Mol Pathol 2012;93:40-9. [PMID: 22525806 DOI: 10.1016/j.yexmp.2012.04.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
153 Yu L, Chen S, Luo N, He S. The C-terminus domain of the hepatitis B virus x protein stimulates the proliferation of mouse foetal hepatic progenitor cells, although it is not required for the formation of spheroids. Int J Mol Med. 2017;40:400-410. [PMID: 28627604 DOI: 10.3892/ijmm.2017.3026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
154 Ceballos MP, Rigalli JP, Ceré LI, Semeniuk M, Catania VA, Ruiz ML. ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma. Curr Med Chem 2019;26:1224-50. [PMID: 29303075 DOI: 10.2174/0929867325666180105103637] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 15.5] [Reference Citation Analysis]
155 Chu TH, Chan HH, Kuo HM, Liu LF, Hu TH, Sun CK, Kung ML, Lin SW, Wang EM, Ma YL, Cheng KH, Lai KH, Wen ZH, Hsu PI, Tai MH. Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN. Oncotarget 2014;5:1475-90. [PMID: 24721996 DOI: 10.18632/oncotarget.1745] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
156 Passman AM, Strauss RP, McSpadden SB, Finch-Edmondson M, Andrewartha N, Woo KH, Diepeveen LA, Zhao W, Fernández-Irigoyen J, Santamaría E, Medina-Ruiz L, Szpakowska M, Chevigné A, Park H, Carlessi R, Tirnitz-Parker JEE, Blanco JR, London R, Callus BA, Elsegood CL, Baker MV, Martínez A, Yeoh GCT, Ochoa-Callejero L. Maraviroc Prevents HCC Development by Suppressing Macrophages and the Liver Progenitor Cell Response in a Murine Chronic Liver Disease Model. Cancers (Basel) 2021;13:4935. [PMID: 34638423 DOI: 10.3390/cancers13194935] [Reference Citation Analysis]
157 Wang HW, Hsieh TH, Huang SY, Chau GY, Tung CY, Su CW, Wu JC. Forfeited hepatogenesis program and increased embryonic stem cell traits in young hepatocellular carcinoma (HCC) comparing to elderly HCC. BMC Genomics 2013;14:736. [PMID: 24160375 DOI: 10.1186/1471-2164-14-736] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
158 Iida H, Osaki R, Matsubara A, Maehira H, Mori H, Fujimoto T, Andoh A, Kushima R, Nakashima O, Kondo F, Tani M. Two cases of benign hepatic nodules caused by sinusoidal dilatation with different hemodynamics. Clin J Gastroenterol 2020;13:873-81. [PMID: 32418022 DOI: 10.1007/s12328-020-01129-0] [Reference Citation Analysis]
159 Li Y, Liu D, Zong Y, Qi J, Li B, Liu K, Xiao H. Developmental Stage-Specific Hepatocytes Induce Maturation of HepG2 Cells by Rebuilding the Regulatory Circuit. Mol Med 2015;21:285-95. [PMID: 25879626 DOI: 10.2119/molmed.2014.00173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
160 Van Haele M, Roskams T. Hepatic Progenitor Cells: An Update. Gastroenterol Clin North Am. 2017;46:409-420. [PMID: 28506372 DOI: 10.1016/j.gtc.2017.01.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
161 Liu Y, Lu LL, Wen D, Liu DL, Dong LL, Gao DM, Bian XY, Zhou J, Fan J, Wu WZ. MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming. J Hematol Oncol 2020;13:12. [PMID: 32033570 DOI: 10.1186/s13045-019-0841-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
162 Szymańska-Chabowska A, Świątkowski F, Jankowska-Polańska B, Mazur G, Chabowski M. Nestin Expression as a Diagnostic and Prognostic Marker in Colorectal Cancer and Other Tumors. Clin Med Insights Oncol 2021;15:11795549211038256. [PMID: 34421318 DOI: 10.1177/11795549211038256] [Reference Citation Analysis]
163 Baharuddin P, Satar N, Fakiruddin KS, Zakaria N, Lim MN, Yusoff NM, Zakaria Z, Yahaya BH. Curcumin improves the efficacy of cisplatin by targeting cancer stem-like cells through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung cancer cell lines. Oncol Rep 2016;35:13-25. [PMID: 26531053 DOI: 10.3892/or.2015.4371] [Cited by in Crossref: 58] [Cited by in F6Publishing: 64] [Article Influence: 9.7] [Reference Citation Analysis]
164 Kim R, Kim SB, Cho EH, Park SH, Park SB, Hong SK, Chae G. CD44 expression in patients with combined hepatocellular cholangiocarcinoma. Ann Surg Treat Res. 2015;89:9-16. [PMID: 26131439 DOI: 10.4174/astr.2015.89.1.9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
165 Shi DM, Shi XL, Xing KL, Zhou HX, Lu LL, Wu WZ. miR-296-5p suppresses stem cell potency of hepatocellular carcinoma cells via regulating Brg1/Sall4 axis. Cell Signal 2020;72:109650. [PMID: 32320856 DOI: 10.1016/j.cellsig.2020.109650] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
166 Maehara O, Sato F, Natsuizaka M, Asano A, Kubota Y, Itoh J, Tsunematsu S, Terashita K, Tsukuda Y, Nakai M, Sho T, Suda G, Morikawa K, Ogawa K, Chuma M, Nakagawa K, Ohnishi S, Komatsu Y, Whelan KA, Nakagawa H, Takeda H, Sakamoto N. A pivotal role of Krüppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma. Cancer Biol Ther 2015;16:1453-61. [PMID: 26176896 DOI: 10.1080/15384047.2015.1070992] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
167 Liu F, Qian Y. The role of CD133 in hepatocellular carcinoma. Cancer Biol Ther 2021;22:291-300. [PMID: 33899676 DOI: 10.1080/15384047.2021.1916381] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
168 Ni XC, Xu J, Yi Y, Fu YP, Cai XY, Liu G, Huang JL, Gan W, Qiu SJ. Inflammation-nutrition score predicts prognosis of patients with resectable hepatocellular carcinoma. Int J Clin Oncol 2019;24:825-35. [PMID: 31020447 DOI: 10.1007/s10147-019-01402-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
169 Jing CY, Fu YP, Zheng SS, Yi Y, Shen HJ, Huang JL, Xu X, Lin JJ, Zhou J, Fan J, Ren ZG, Qiu SJ, Zhang BH. Prognostic nomogram for patients with hepatocellular carcinoma underwent adjuvant transarterial chemoembolization following curative resection. Medicine (Baltimore) 2017;96:e6140. [PMID: 28296727 DOI: 10.1097/MD.0000000000006140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
170 Svinka J, Mikulits W, Eferl R. STAT3 in hepatocellular carcinoma: new perspectives. Hepatic Oncol. 2013;1:107-120. [PMID: 30190945 DOI: 10.2217/hep.13.7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
171 Zhu M, Li W, Lu Y, Dong X, Lin B, Chen Y, Zhang X, Guo J, Li M. HBx drives alpha fetoprotein expression to promote initiation of liver cancer stem cells through activating PI3K/AKT signal pathway. Int J Cancer 2017;140:1346-55. [PMID: 27925189 DOI: 10.1002/ijc.30553] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 9.5] [Reference Citation Analysis]
172 Tampaki EC, Nakopoulou L, Tampakis A, Kontzoglou K, Weber WP, Kouraklis G. Nestin involvement in tissue injury and cancer--a potential tumor marker? Cell Oncol (Dordr) 2014;37:305-15. [PMID: 25164879 DOI: 10.1007/s13402-014-0193-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
173 Lei Y, Wang X, Sun H, Fu Y, Tian Y, Yang L, Wang J, Xia F. Association of Preoperative NANOG-Positive Circulating Tumor Cell Levels With Recurrence of Hepatocellular Carcinoma. Front Oncol 2021;11:601668. [PMID: 34123777 DOI: 10.3389/fonc.2021.601668] [Reference Citation Analysis]
174 Shi JH, Scholz H, Huitfeldt HS, Line PD. The effect of hepatic progenitor cells on experimental hepatocellular carcinoma in the regenerating liver. Scand J Gastroenterol. 2014;49:99-108. [PMID: 24188385 DOI: 10.3109/00365521.2013.854406] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
175 Chen H, Cai J, Wang J, Qiu Y, Jiang C, Wang Y, Wang Y, Yi C, Guo Lv, Pan L, Guan Y, Zheng J, Qiu D, Du C, Liu Q, Chen G, Yang Y, Xu Y, Xiang AP, Zhang Q. Targeting Nestin+ hepatic stellate cells ameliorates liver fibrosis by facilitating TβRI degradation. J Hepatol 2021;74:1176-87. [PMID: 33217494 DOI: 10.1016/j.jhep.2020.11.016] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
176 Joo I, Kim H, Lee JM. Cancer stem cells in primary liver cancers: pathological concepts and imaging findings. Korean J Radiol. 2015;16:50-68. [PMID: 25598674 DOI: 10.3348/kjr.2015.16.1.50] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
177 Schneller D, Angel P; Division of Signal Transduction and Growth Control, DKFZ-ZMBH Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany, Division of Signal Transduction and Growth Control, DKFZ-ZMBH Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany. Cellular Origin of Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 1-28. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
178 Matsuda Y, Hagio M, Ishiwata T. Nestin: A novel angiogenesis marker and possible target for tumor angiogenesis. World J Gastroenterol 2013; 19(1): 42-48 [PMID: 23326161 DOI: 10.3748/wjg.v19.i1.42] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 74] [Article Influence: 9.3] [Reference Citation Analysis]
179 Guo Z, Zhong JH, Jiang JH, Zhang J, Xiang BD, Li LQ. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis. Ann Surg Oncol. 2014;21:3069-3076. [PMID: 24728740 DOI: 10.1245/s10434-014-3704-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
180 Jiang AG, Chen HL, Lu HY. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer. BMC Cancer 2015;15:386. [PMID: 25956656 DOI: 10.1186/s12885-015-1403-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]